NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of TCR2 Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR2 will receive 1.5117 ADS of Adaptimmune for each share of TCR2 that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit .
Contacts
Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857
